PhaseBio Pharmaceuticals Probability of Future Pink Sheet Price Finishing Under 0.00
| PHASQDelisted Stock | USD 0.0003 0.0001 25.00% |
PhaseBio |
PhaseBio Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of PhaseBio Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for PhaseBio Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| PhaseBio Pharmaceuticals is not yet fully synchronised with the market data | |
| PhaseBio Pharmaceuticals has some characteristics of a very speculative penny stock | |
| PhaseBio Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| PhaseBio Pharmaceuticals has accumulated 1.36 M in total debt. PhaseBio Pharmaceuticals has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist PhaseBio Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, PhaseBio Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PhaseBio Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PhaseBio to invest in growth at high rates of return. When we think about PhaseBio Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 10.83 M. Net Loss for the year was (131.07 M) with loss before overhead, payroll, taxes, and interest of (91.28 M). | |
| PhaseBio Pharmaceuticals has accumulated about 7.8 M in cash with (47.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
PhaseBio Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of PhaseBio Pink Sheet often depends not only on the future outlook of the current and potential PhaseBio Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. PhaseBio Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 48.2 M |
PhaseBio Pharmaceuticals Technical Analysis
PhaseBio Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. PhaseBio Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of PhaseBio Pharmaceuticals. In general, you should focus on analyzing PhaseBio Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
PhaseBio Pharmaceuticals Predictive Forecast Models
PhaseBio Pharmaceuticals' time-series forecasting models is one of many PhaseBio Pharmaceuticals' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary PhaseBio Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about PhaseBio Pharmaceuticals
Checking the ongoing alerts about PhaseBio Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for PhaseBio Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| PhaseBio Pharmaceuticals is not yet fully synchronised with the market data | |
| PhaseBio Pharmaceuticals has some characteristics of a very speculative penny stock | |
| PhaseBio Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| PhaseBio Pharmaceuticals has accumulated 1.36 M in total debt. PhaseBio Pharmaceuticals has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist PhaseBio Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, PhaseBio Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PhaseBio Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PhaseBio to invest in growth at high rates of return. When we think about PhaseBio Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 10.83 M. Net Loss for the year was (131.07 M) with loss before overhead, payroll, taxes, and interest of (91.28 M). | |
| PhaseBio Pharmaceuticals has accumulated about 7.8 M in cash with (47.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in PhaseBio Pink Sheet
If you are still planning to invest in PhaseBio Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PhaseBio Pharmaceuticals' history and understand the potential risks before investing.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |